Australian investment professionals believe the country's biotech industry may be turning the corner from one plagued with false starts and disappointments to one producing milestones with more products entering late-stage trials. But the sector remains a risky one with a long wait for a payback and still requires careful research on the part of the investor.

Related Summaries